WO2000064261A1 - Role du facteur-b (vegf-b) de croissance endotheliale dans le developpement osseux et utilisations correspondantes - Google Patents

Role du facteur-b (vegf-b) de croissance endotheliale dans le developpement osseux et utilisations correspondantes Download PDF

Info

Publication number
WO2000064261A1
WO2000064261A1 PCT/US2000/011096 US0011096W WO0064261A1 WO 2000064261 A1 WO2000064261 A1 WO 2000064261A1 US 0011096 W US0011096 W US 0011096W WO 0064261 A1 WO0064261 A1 WO 0064261A1
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
bone
sequence
amino acid
seq
Prior art date
Application number
PCT/US2000/011096
Other languages
English (en)
Other versions
WO2000064261A9 (fr
Inventor
Karin Aase
Arja Kaipainen
Birgitta Olofsson
Kari Alitalo
Ulf Eriksson
Original Assignee
Ludwig Institute For Cancer Research
Helsinki University Licensing Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute For Cancer Research, Helsinki University Licensing Ltd. filed Critical Ludwig Institute For Cancer Research
Priority to AU46624/00A priority Critical patent/AU4662400A/en
Publication of WO2000064261A1 publication Critical patent/WO2000064261A1/fr
Publication of WO2000064261A9 publication Critical patent/WO2000064261A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Definitions

  • This invention relates generally to methods utilizing the growth factor VEGF-B, and specifically to methods utilizing VEGF-B to affect the growth of bones.
  • the two major components of the mammalian vascular system are the endothelial and smooth muscle cells.
  • the endothelial cells form the lining of the inner surface of all blood vessels and lymphatic vessels in the mammal .
  • the formation of new blood vessels can occur by two different processes, vasculogenesis or angiogenesis (for review see Risau, W. , Nature 386: 671-674, 1997).
  • Vasculogenesis is characterized by the in si tu differentiation of endothelial cell precursors to mature endothelial cells and association of these cells to form vessels, such as occurs in the formation of the primary vascular plexus in the early embryo.
  • angiogenesis the formation of blood vessels by growth and branching of pre-existing vessels, is important in later embryogenesis and is responsible for the blood vessel growth which occurs in the adult .
  • Angiogenesis is a physiologically complex process involving proliferation of endothelial cells, degradation of extracellular matrix, branching of vessels and subsequent cell adhesion events.
  • angiogenesis is tightly controlled and limited under normal circumstances to the female reproductive system.
  • angiogenesis can be switched on in response to tissue damage.
  • solid tumors are able to induce angiogenesis in surrounding tissue, thus sustaining tumor growth and facilitating the formation of metastases (Folkman, J., Nature Med. 1: 27-31, 1995) .
  • Angiogenesis is also involved in a number of pathologic conditions, where it plays a role or is involved directly in different sequelae of the disease.
  • Some examples include neovascularization associated with various liver diseases, neovascular sequelae of diabetes, neovascular sequelae to hypertension, neovascularization in post-trauma, neovascularization due to head trauma, neovascularization in chronic liver infection (e.g. chronic hepatitis) , neovascularization due to heat or cold trauma, dysfunction related to excess of hormone, creation of hemangiomas and restenosis following angioplasty.
  • angiogenesis is useful in preventing, treating or alleviating these pathological conditions and to reduce blood supply to solid tumors.
  • factors involved in the control of angiogenesis have been intensively investigated.
  • a number of growth factors have been shown to be involved in the regulation of angiogenesis; these include fibroblast growth factors (FGFs) , platelet-derived growth factor (PDGF) , transforming growth factor alpha (TGF ⁇ ) , and hepatocyte growth factor (HGF) .
  • FGFs fibroblast growth factors
  • PDGF platelet-derived growth factor
  • TGF ⁇ transforming growth factor alpha
  • HGF hepatocyte growth factor
  • VEGFs vascular endothelial growth factors
  • RTKs endothelial receptor tyrosine kinases
  • VEGF-B described in International Patent Application PCT/US96/02957 (WO 96/26736) and in U.S. Patents 5,840,693 and 5,607,918 by Ludwig Institute for Cancer Research and The University of Helsinki VEGF-C or VEGF2 , described in Joukov et al . , EMBO J. , 15 290-298, 1996, Lee et al . , Proc . Na tl . Acad . Sci .
  • VEGF-D described in International Patent Application No. PCT/US97/14696 (WO 98/07832), and Achen et al . , Proc . Na tl . Acad . Sci . USA, 95: 548-553, 1998; the placenta growth factor (PlGF) , described in aglione et al . , Proc. Natl. Acad. Sci. USA, 88: 9267-9271, 1991; and VEGF3 , described in International Patent Application No.
  • VEGF family member has between 30% and 45% amino acid sequence identity with VEGF.
  • the VEGF family members share a VEGF homology domain which contains the six cysteine residues which form the cystine-knot motif.
  • Functional characteristics of the VEGF family include varying degrees of mitogenicity for endothelial cells, induction of vascular permeability and angiogenic and lymphangiogenic properties.
  • VEGF Vascular endothelial growth factor
  • VEGF has strong chemoattractant activity towards monocytes, can induce the plasminogen activator and the plasminogen activator inhibitor in endothelial cells, and can also induce microvascular permeability. Because of the latter activity, it is sometimes referred to as vascular permeability factor (VPF) .
  • VEGF is also chemotactic for certain hematopoetic cells. Recent literature indicates that VEGF blocks maturation of dendritic cells and thereby reduces the effectiveness of the immune response to tumors (many tumors secrete VEGF) (Gabrilovich et al . , Blood 92: 4150-4166, 1998; Gabrilovich et al . , Clinical Cancer Research 5: 2963- 2970, 1999) .
  • VEGF-B has similar angiogenic and other properties to those of VEGF, but is distributed and expressed in tissues differently from VEGF.
  • VEGF-B is very strongly expressed in heart, and only weakly in lung, whereas the reverse is the case for VEGF. This suggests that VEGF and VEGF-B, despite the fact that they are co-expressed in many tissues, may have functional differences.
  • VEGF-B was isolated using a yeast co-hybrid interaction trap screening technique by screening for cellular proteins which might interact with cellular retinoic acid-binding protein type I (CRABP-I) . Its isolation and characteristics are described in detail in PCT/US96/02957 (WO 96/26736) , in U.S. Patents 5,840,693 and 5,607,918 by Ludwig Institute for Cancer Research and The University of Helsinki and in Olofsson et al., Proc . Natl . Acad. Sci . USA, 93: 2576-2581, 1996. The entire disclosure of the International Patent Application PCT/US96/02957 (WO 96/26736), of U.S.
  • VEGF-C was isolated from conditioned media of the PC-3 prostate adenocarcinoma cell line (CRL1435) by screening for ability of the medium to produce tyrosine phosphorylation of the endothelial cell-specific receptor tyrosine kinase VEGFR-3 (Flt4) , using cells transfected to express VEGFR-3.
  • VEGF-C was purified using affinity chromatography with recombinant VEGFR-3, and was cloned from a PC-3 cDNA library. Its isolation and characteristics are described in detail in Joukov et al . , EMBO J. , 15: 290-298, 1996.
  • VEGF-D was isolated from a human breast cDNA library, commercially available from Clontech, by screening with an expressed sequence tag obtained from a human cDNA library designated "Soares Breast 3NbHBst" as a hybridization probe (Achen et al . , Proc . Natl . Acad . Sci . USA, 95: 548-553,, 1998). Its isolation and characteristics are described in detail in International Patent Application No. PCT/US97/14696 (WO98/07832) .
  • VEGF-D The VEGF-D gene is broadly expressed in the adult human, but is certainly not ubiquitously expressed. VEGF-D is strongly expressed in heart, lung and skeletal muscle. Intermediate levels of VEGF-D are expressed in spleen, ovary, small intestine and colon, and a lower expression occurs in kidney, pancreas, thymus, prostate and testis. No VEGF-D mRNA was detected in RNA from brain, placenta, liver or peripheral blood leukocytes.
  • PlGF was isolated from a term placenta cD ⁇ A library. Its isolation and characteristics are described in detail in aglione et al . , Proc . Natl . Acad. Sci . USA, 88: 9267-9271,
  • VEGF3 was isolated from a cD ⁇ A library derived from colon tissue. VEGF3 is stated to have about 36% identity and 66% similarity to VEGF. The method of isolation of the gene encoding VEGF3 is unclear and no characterization of the biological activity is disclosed.
  • Similarity between two proteins is determined by comparing the amino acid sequence and conserved amino acid substitutions of one of the proteins to the sequence of the second protein, whereas identity is determined without including the conserved amino acid substitutions.
  • receptor tyrosine kinases are glycoproteins, which consist of an extracellular domain capable of binding a specific growth factor (s), a transmembrane domain, which is usually an alpha-helical portion of the protein, a juxtamembrane domain, which is where the receptor may be regulated by, e.g., protein phosphorylation, a tyrosine kinase domain, which is the enzymatic component of the receptor and a carboxy-terminal tail, which in many receptors is involved in recognition and binding of the substrates for the tyrosine kinase.
  • s specific growth factor
  • transmembrane domain which is usually an alpha-helical portion of the protein
  • juxtamembrane domain which is where the receptor may be regulated by, e.g., protein phosphorylation
  • a tyrosine kinase domain which is the enzymatic component of the receptor and a carboxy-terminal tail, which
  • VEGFR-1 Flt-1
  • VEGFR-2 KDR/Flk-1
  • VEGFR-3 Flt4
  • Tie Tie
  • Tek/Tie-2 Tek/Tie-2
  • VEGFR-1 The only receptor tyrosine kinases known to bind VEGFs are VEGFR-1, VEGFR-2 and VEGFR-3.
  • VEGFR-1 and VEGFR-2 bind VEGF with high affinity, and VEGFR-1 also binds VEGF-B and PlGF.
  • VEGF-C has been shown to be the ligand for VEGFR-3, and it also activates VEGFR-2 (Joukov et al . , The EMBO Journal , 15: 290-298, 1996).
  • VEGF-D binds to both VEGFR-2 and VEGFR-3 (Achen et al., Proc . Natl . Acad. Sci . USA, 95: 548-553, 1998).
  • a ligand for Tek/Tie-2 has been described in International Patent Application No. PCT/US95/12935 (WO 96/11269) by Regeneron Pharmaceuticals, Inc. The ligand for Tie has not yet been identified.
  • VEGF vascular endothelial growth factor
  • the VEGF receptor was found to specifically bind the VEGF 165 isoform via the exon 7 encoded sequence, which shows weak affinity for heparin (Soker et al . , Cell , 92: 735- 745, 1998) .
  • the receptor was shown to be identical to human neuropilin-1 (NP-1) , a receptor involved in early stage neuromorphogenesis .
  • NP-1 human neuropilin-1
  • P1GF-2 also appears to interact with NP-1 (Migdal et al . , J " . Biol . Chem . , 273: 22272- 22278, 1998) .
  • VEGFR-1, VEGFR-2 and VEGFR-3 are expressed differently by endothelial cells.
  • both VEGFR-1 and VEGFR-2 are expressed in blood vessel endothelia (Oelrichs et al . , Oncogene, 8: 11-18, 1992; Kaipainen et al . , J. Exp. Med . , 178: 2077-2088, 1993; Dumont et al . , Dev. Dyn . , 203: 80-92, 1995; Fong et al . , Dev. Dyn . , 207: 1-10, 1996) and VEGFR-3 is mostly expressed in the lymphatic endothelium of adult tissues
  • VEGFR-3 is also expressed in the blood vasculature surrounding tumors .
  • VEGFR-1 is mainly expressed in endothelial cells during development, it can also be found in hematopoetic precursor cells during early stages of embryogenesis (Fong et al . , Nature, 376: 66-70, 1995). In adults, monocytes and macrophages also express this receptor (Barleon et al . , Blood, 87: 3336-3343, 1995).
  • VEGFR-1 is expressed by most, if not all, vessels (Breier et al . , Dev. Dyn . , 204: 228-239, 1995; Fong et al . , Dev. Dyn . , 207: 1-10, 1996).
  • VEGFR-1 is expressed in all tissues expressing VEGF-B suggesting that VEGF-B is a physiological ligand for VEGFR- 1.
  • VEGFR-3 The receptor VEGFR-3 is widely expressed on endothelial cells during early embryonic development but as embryogenesis proceeds becomes restricted to venous endothelium and then to the lymphatic endothelium (Kaipainen et al . , Cancer Res . , 54: 6571-6577, 1994; Kaipainen et al . , Proc . Na tl . Acad . Sci . USA, 92: 3566-3570, 1995). VEGFR-3 is expressed on lymphatic endothelial cells in adult tissues. This receptor is essential for vascular development during embryogenesis.
  • VEGFR-1 The essential, specific role in vasculogenesis, angiogenesis and/or lymphangiogenesis of VEGFR-1, VEGFR-2, VEGFR-3, Tie and Tek/Tie-2 has been demonstrated by targeted mutations inactivating these receptors in mouse embryos. Disruption of the VEGFR genes results in aberrant development of the vasculature leading to embryonic lethality around midgestation. Analysis of embryos carrying a completely inactivated VEGFR-1 gene suggests that this receptor is required for functional organization of the endothelium (Fong et al . , Nature, 376: 66-70, 1995).
  • VEGFR-3 is required for the maturation of primary vascular networks into larger blood vessels.
  • VEGFR-3 plays a role in development of the lymphatic vasculature and lymphangiogenesis given its specific expression in lymphatic endothelial cells during embryogenesis and adult life. This is supported by the finding that ectopic expression of VEGF-C, a ligand for VEGFR-3, in the skin of transgenic mice, resulted in lymphatic endothelial cell proliferation and vessel enlargement in the dermis.
  • VEGF-C may have a primary function in lymphatic endothelium, and a secondary function in angiogenesis and permeability regulation which is shared with VEGF (Joukov et al . , EMBO J. , 15: 290-298, 1996) .
  • VEGF-B is most closely related to VEGF (Olofsson et al . , Proc . Na tl . Acad . Sci . USA, 1996, 93: 2576-2581).
  • VEGF-B has similar angiogenic and other properties to those of VEGF, but is distributed and expressed in tissues differently from VEGF. This suggests that VEGF and VEGF-B, despite, the fact that they are co-expressed in many tissues, may have functional differences.
  • VEGF-B is expressed in several tissues and most abundantly in the heart, brain, skeletal muscle and kidney and occurs as two splice isoforms of 167 and 186 amino acids, respectively (Olofsson et al . , Proc . Natl . Acad . Sci . USA, 1996, 93: 2576-2581; Olofsson et al . , J. Biol . Chem. , 1996 271: 19310-19317) . Because VEGF-B binds VEGFR-1, it may have a role in the regulation of blood vessel physiology.
  • the invention generally provides methods utilizing the growth factor VEGF-B, and specifically to methods utilizing VEGF-B to affect the growth of bones .
  • a method for stimulating vascularization of a bone by angiogenesis comprises the step of administering an effective angiogenesis stimulating amount of a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4 (VEGF-B isoforms: hVEGF-B 167 and hVEGF-B 186 , respectively) or a fragment thereof having the biological activity of VEGF-B.
  • VEGF-B collectively refers to a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO : 2 or 4 , or fragments thereof as herein defined, and to a polynucleotide sequence which can code for a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO : 2 or 4, or a fragment thereof having the biological activity of VEGF-B.
  • This nucleotide sequence/polynucleotides can be naked and/or in a vector or liposome.
  • the angiogenesis stimulating amount of VEGF-B or a fragment thereof can be provide by the use of an expression vector comprising a nucleotide sequence which codes for VEGF-B
  • SEQ ID NO:l or 3 or a fragment thereof having the biological activity of VEGF-B, or a polynucleotide coding for a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4 (see, for example, SEQ ID NO: 1 or 3), or a fragment thereof having the biological activity of VEGF-B.
  • This method can be used for bones which include, but are not limited to, long bones and vertebrae.
  • VEGF-B The abilities referred to herein as "biological activities of VEGF-B" and can be readily tested by methods known in the art.
  • the polypeptide or the encoded polypeptide from a polynucleotide has the ability to stimulate one or more of endothelial cell proliferation, differentiation, migration, survival or vascular permeability including, but not limited to, proliferation, differentiation, migration, survival or vascular permeability of vascular endothelial cells and/or lymphatic endothelial cells.
  • VEGF-B can also have antagonistic effects on cells which have hitherto not been described, but are included in the biological activities of VEGF-B.
  • Polypeptides comprising conservative substitutions, insertions, or deletions, but which still retain the biological activity of VEGF-B are clearly to be understood to be within the scope of the invention.
  • Persons skilled in the art will be well aware of methods which can readily be used to generate such polypeptides, for example the use of site- directed mutagenesis, or specific enzymatic cleavage and ligation.
  • the skilled person will also be aware that peptidomimetic compounds or compounds in which one or more amino acid residues are replaced by a non-naturally occurring amino acid or an amino acid analog may retain the required aspects of the biological activity of VEGF-B.
  • Such compounds can readily be made and tested by methods known in the art, and are also within the scope of the invention.
  • allelic variants of the nucleic acid sequence encoding VEGF-B are encompassed within the scope of the invention.
  • Allelic variants are well known in the art, and represent alternative forms or a nucleic acid sequence which comprise substitution, deletion or addition of one or more nucleotides, but which do not result in any substantial functional alteration of the encoded polypeptide.
  • Preferred vectors of the invention are expression vectors in which a nucleic acid according to the invention is operatively connected to one or more appropriate promoters and/or other control sequences, such that appropriate host cells transformed or transfected with the vectors are capable of expressing VEGF-B, or a fragment thereof having the biological activity of VEGF-B.
  • Other preferred vectors are those suitable for transfection of mammalian cells, or for gene therapy, such as adenoviral- or retroviral-based vectors or liposomes. A variety of such vectors is known in the art.
  • VEGF-B a fragment thereof having the biological activity of VEGF-B may be administered together with, or in conjunction with, one or more of VEGF, VEGF-C, VEGF-D, VEGF-F, PlGF, PDGF-A, PDGF-B, FGF and/or heparin.
  • a method for stimulating the healing of bone fractures or breaks comprises the step of administering an angiogenesis stimulating amount of a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4, or a fragment thereof having the biological activity of VEGF-B, or a polynucleotide coding for a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4, or a fragment thereof having the biological activity of VEGF-B.
  • a method for enhancing the acceptance and/or securing of an implant to a bone.
  • This method comprises the steps of applying an implant to a bone; and administering an effective angiogenesis stimulating amount of VEGF-B, or a fragment or analog thereof having the biological activity of VEGF-B, a polynucleotide coding for a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4, or a fragment thereof having the biological activity of VEGF-B.
  • a method of treatment or alleviation of the inflammation of an epiphysis of a long bone comprises the step of administering an effective inflammation inhibiting amount of an antagonist to a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4, or a fragment thereof having the biological activity of VEGF-B.
  • the antagonist may be any agent that prevents the action of VEGF-B, either by preventing the binding of VEGF-B to its corresponding receptor on the target cell, or by preventing activation of the receptor.
  • Suitable antagonists include, but are not limited to, antibodies directed against VEGF-B; competitive or non-competitive inhibitors of binding of VEGF-B to its corresponding receptor; and anti-sense nucleotide sequences as described below.
  • VEGF-B or a VEGF-B antagonist is to be used for therapeutic purposes
  • the dose and route of application will depend upon the nature of the patient and condition to be treated, and will be at the discretion of the attending physician or veterinarian. Suitable routes include oral, subcutaneous, intramuscular, intraperitoneal or intravenous injection, parenteral, topical application, implants etc. Topical application of VEGF-B may be used in a manner analogous to VEGF.
  • an effective amount of the truncated active form of VEGF-B is administered to an organism in need thereof in a dose between about 0.1 and 1000 ⁇ g/kg body weight.
  • VEGF-B or a VEGF-B antagonist may be employed in combination with a suitable pharmaceutical carrier.
  • suitable pharmaceutical carrier Such compositions comprise a therapeutically effective amount of
  • VEGF-B or a VEGF-B antagonist and a pharmaceutically acceptable non-toxic salt thereof, and a pharmaceutically acceptable solid or liquid carrier or adjuvant.
  • a carrier or adjuvant include, but are not limited to, saline, buffered saline, Ringer's solution, mineral oil, talc, corn starch, gelatin, lactose, sucrose, microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate, sodium chloride, alginic acid, dextrose, water, glycerol, ethanol, thickeners, stabilizers, suspending agents and combinations thereof.
  • compositions may be in the form of solutions, suspensions, tablets, capsules, creams, salves, elixirs, syrups, wafers, ointments or other conventional forms.
  • Compositions which comprise VEGF-B may optionally further comprise one or more of VEGF, PDGF-A, PDGF-B, VEGF-C, VEGF-D, PlGF and/or heparin.
  • Compositions comprising VEGF-B will contain from about 0.1% to 90% by weight of the active compound(s), and most generally from about 10% to 30%.
  • a sterile formulation preferably a suitable soluble salt form of the truncated active form of VEGF-B, such as hydrochloride salt
  • a pharmaceutical diluent such as pyrogen-free water (distilled) , physiological saline or 5% glucose solution.
  • a suitable insoluble form of the compound may be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, e.g. an ester of a long chain fatty acid such as ethyl oleate.
  • the preferred anti-sense nucleotide sequence is complementary to at least a part of a DNA sequence which encodes a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4 , or a fragment thereof that has the biological activity of VEGF-B.
  • the anti-sense nucleotide sequence can be to the promoter region of the VEGF-B gene or other non- coding region of the gene which may be used to inhibit, or at least mitigate, VEGF-B expression.
  • a further aspect of the invention involves the use of a pharmaceutical composition which comprises an effective angiogenesis stimulating amount of a polypeptide having an amino acid sequence of at least 85% sequence identity with the sequence of SEQ ID NO: 2 or 4, or a fragment thereof having the biological activity of VEGF-B, and a pharmaceutically acceptable non-toxic salt thereof, and a pharmaceutically acceptable solid or liquid carrier or adjuvant or diluent to stimulate angiogenesis of a bone.
  • VEGF-B forms both homodimers and heterodimers with VEGF.
  • the invention includes both homodimers of VEGF-B polypeptide and heterodimers of VEGF-B and VEGF, VEGF-C, VEGF-D, PlGF, PDGF-A or PDGF-B.
  • VEGF-B polypeptide
  • VEGF-C vascular endothelial growth factor
  • VEGF-D vascular endothelial growth factor-B
  • PlGF PlGF
  • PDGF-A or PDGF-B PDGF-A or PDGF-B.
  • Figure 1A-C shows analyses of mouse VEGF-B 186 and mVEGF-B exonl . 5 from baculovirus-infected Sf9 insect cells;
  • Figure 2A-H shows immunohistochemical localization of VEGF-B in the developing heart and large vessels
  • Figure 3A-H shows immunohistochemical localization of VEGF-B in developing muscle, developing long bone, cartilage and glandular tissues.
  • VEGF-B in the vascularization of developing bones is suggested based on the pattern of expression of this growth factor.
  • VEGF-B can be used to stimulate vascularization of a bone by angiogenesis which can be used to stimulate the healing process of a damaged bone or enhance the acceptance and/or securing of an implant to a bone.
  • angiogenesis which can be used to stimulate the healing process of a damaged bone or enhance the acceptance and/or securing of an implant to a bone.
  • mVEGF-B 186 and mVEGF-B exonl _ 5 were tagged at the amino terminus with 6X Histidine residues and then expressed in baculovirus-infected Sf9 cells.
  • the baculovirus expression vector pACGP67A was a gift from Dr. Johanna Veijola.
  • Full length mVEGF-B 186 cDNA (SEQ ID NO: 5) was amplified by polymerase chain reaction (PCR) using two primers to allow direct cloning into the expression vector and including the appropriate modifications of the expressed protein; sense 5 ' -ATC GAG ATC TTC ATC ACC ATC ACC ATC ACG GAG ATG ACG ATG ACA AAC CTG TGT CCC AGT TT-3 ' (SEQ ID NO:6) (including a Bgl II site for in frame cloning and a 6X Histidine tail and enterokinase site, but excluding the endogenous signal sequence) antisense 5 ' -AGC TAG ATC TCT AAG CCC CGC CCT TG-3 ⁇ (SEQ ID NO: 7) (including a Bgl II site for cloning) .
  • PCR polymerase chain reaction
  • Recombinant baculovirus was generated in Sf9 cells (obtained from ATCC) and reamplified and the titer of the virus stocks was determined as recommended by the supplier (Pharmingen Baculovirus Expression Vector System: Procedures and Methods Manual) .
  • the Sf-9 cells were maintained in medium (Nordcell TNM-FH lx without L-glutamine) containing 10% fetal bovine serum (Gibco BRL) .
  • the Sf9 cells were adapted in four steps to serum free medium (Sf 900 II SMF, Gibco BRL) , and the cells were infected with a multiplicity of infection of 7 at a density of 2 X 10 6 cells/ml.
  • Medium containing recombinant protein was harvested
  • the eluted proteins were analyzed on 12.5% acrylamide gels under reducing and nonreducing conditions.
  • the proteins were electrotransferred onto Hybond filters for 45 min.
  • the recombinant proteins on the blots were visualized using an antipeptide Ig against the N-terminus (Olofsson et al . , Proc . Natl . Acad . Sci . USA, 1996 93: 2576-2581.) ( Figure 1A) or using a rabbit antiserum raised against a glutathionine-S-transferase fusion protein containing the unique C-terminal amino acid residues of mVEGF-B 186 ( Figure IC) .
  • mVEGF-B The highly purified mVEGF-B 186 was used to immunize rabbits. 25 ⁇ g of protein was emulsified in 500 ⁇ l of Freunds Complete Adjuvant and injected intradermally. The rabbits were boostered at biweekly intervals with the same amounts of protein emulsified in Freunds Incomplete Adjuvant. Affinity purified Ig to mVEGF-B 186 was obtained by passing immune sera over a Sepharose 4B column (Pharmacia Biotech) containing immobilized mVEGF-B 186 . Following extensive washing, the bound Igs were eluted in 300 mM sodium citrate buffer pH 3.0 containing 500 mM NaCl . Eluted Igs were dialyzed against PBS and concentrated.
  • Figure 1A shows the immunoblot analysis under non- reducing conditions (-) and reducing (+) conditions using the antipeptide Ig against the N-terminus.
  • Immunoblot analysis of the eluates under non-reducing conditions revealed that both proteins are disulfide-linked homodimers migrating with apparent molecular weights of 48-55,000 and 34,000, respectively, and significant amounts of both proteins appeared as high molecular weight smears.
  • the 186 isoform migrated as 30-32 kDa species while the truncated protein, mVEGF-B exonl _ 5 , appeared as a homogenous 21 kDa species.
  • the immunoglobulins raised to mVEGF-B 186 also react with mVEGF-B exonl . s and mVEGF-B 167 .
  • the molecular weight standards are indicated to the left in the Figure .
  • Figure IB shows the SDS-PAGE analysis of highly purified recombinant mVEGF-B 186 analyzed under non-reducing (-) and reducing (+) conditions. The separated proteins were visualized by staining with Coomassie Brilliant Blue.
  • FIG. IC shows that the affinity-purified Igs were specific only for VEGF-B.
  • the Igs to VEGF-B recognize the common N-terminal domain of the various mVEGF-B isoforms generated either by alternative splicing of mRNA or by proteolytic processing of mVEGF-B 186 , and show no cross-reactivity with several other VEGF members.
  • VEGF-B protein in mouse embryos were determined by immunohistochemistry using standard procedures and employing affinity purified Ig fractions on tissue sections of E10.5 to
  • the embryos were fixed in 4% paraformaldehyde overnight at 4°C and processed for cryosectioning. 14 ⁇ m cryosections were used for the stainings.
  • the slides were air dried for 1 to 3 hours followed by a 10 minute post fixation with 4% paraformaldehyde .
  • PBS phosphate buffered saline
  • PBS-T Triton X-100
  • the slides were incubated in 0.3% H 2 0 2 in PBS-T for 30 minutes to quench the endogenous peroxidase activity. This was followed by washing 2 x 5 minutes with PBS-T and 2 x 5 minutes in PBS.
  • Blocking of non-specific binding was done using 3% bovine serum albumin (BSA) in PBS for 30 minutes.
  • the slides were incubated with the affinity purified antibody against mVEGF-B at a concentration of 0.5 ⁇ g/ml overnight in 4°C. After washing, the slides were incubated with the secondary Ig (goat anti-rabbit HRP, Vector Laboratories) at a dilution of 1:200 for 1 hour. After washing, the slides were incubated with the AB complex (Vector Laboratories) for 1 hour and washed with Tris pH 7.4.
  • BSA bovine serum albumin
  • DAB 3, 3 ' -diaminobenzidine tetrahydrochloride
  • AEC 3 -amino- 9 -ethyl carbazole
  • the reaction was quenched by washing in Tris-HCl buffer.
  • the anti mVEGF-B Ig was either preabsorbed with a 10X molar excess of mVEGFB ⁇ 86 , tissue sections were incubated with only the secondary Ig or preimmune rabbit IgG was used as the primary antibody.
  • FIG. 2B and 2C shows that the immunostaining was confined to the cardiac myocytes of the atria and the ventricles while the developing atrioventricular septal region, formed largely from the endocardial cushion tissue, was negative. Intense staining for VEGF-B was seen in the outflow tract proximal to the heart while more distally, the outflow tract lacked detectable expression.
  • Figure 2B and 2D shows that no staining of the endothelial cells was seen in the outflow tract, in the endocardium or epicardium.
  • Figure 2D also shows that, at higher magnification, the cardiac myocytes showed an intracellular staining with a preferential perinuclear localization. The extracellular matrix surrounding the cardiac myocytes also showed some immunoreactivity.
  • vascular smooth muscle cells showed no expression of VEGF-B, but around E12.5, these cells became positive, with staining around several of the larger vessels, e.g. the dorsal aorta, the carotid artery and the subclavian artery.
  • Figure 2G shows that at E14.5, VEGF-B also appeared in the vascular smooth muscle cells of the intervertebral and lung vessels and in the arteries of the kidney at E15.5.
  • E17.5 staining was seen also in the arterial smooth muscle cells of brown fat and intestine.
  • no expression was seen in the endothelial cells of any vessels.
  • Figure 2E shows that in the aorta, VEGF-B staining of the smooth muscle cell layer was weak, with scattered positive cells.
  • Figure 2H shows that VEGF-B was not expressed in the tonic smooth muscle cells of the aortic arch. Expression in the developing muscles
  • VEGF-B was detected in myoblasts of the intersegmental muscles in the developing vertebral column in E12.5 embryos. At the later stages, E15.5 and 17.5, all skeletal muscles were positive, including the muscles of the extremities, the vibrissae etc. Expression of VEGF-B in the muscle cells of the tongue and extrinsic ocular muscles was first detected around E12. Subcutaneous muscles started to express VEGF-B at E14.5 and the muscles associated with the hair follicles at E15.5.
  • Figure 3C shows that VEGF-B was detected in dorsolaterally located cells of the diaphragm at E 12.5, and the positive area expanded until by E15.5 the entire diaphragm was strongly stained.
  • VEGF-B vascular endothelial growth factor-B
  • the staining was confined to the dorsal aspects of the developing ribs and the perichondrium surrounding the hypertrophic chondrocytes .
  • the staining was transiently detected starting at E14.5, with a peak at E15.5 ( Figure 3E) and weaker expression again at E17.5.
  • the same pattern of expression was observed in the vertebra where strong expression was detected at E15.5 and weaker at E17.5.
  • VEGF-B As seen in Figure 3D, the long bones on the other hand showed a strong expression of VEGF-B at E14.5. A weaker expression was seen in E15.5 and 17.5. The stained area was cap-like and covered the epiphysis of the growing bone. The chondrocytes of the cartilage and the ossifying bone appeared negative. No staining for VEGF-B was obtained in association with the developing skull bones.
  • VEGF-B Staining of VEGF-B was obtained in the cytoplasm of chondrocytes within Meckel ' s cartilage and the hyoid cartilage, starting at E12.5 and ending between E15.5 and E17.5 when the cartilage became ossified ( Figure 3F) .
  • Most bones of the developing embryo are formed by endochondral ossification, i.e. the cartilage is replaced by bone in ossification centers, starting in several locations in the embryo from E14.5 onwards.
  • the avascular cartilage is replaced by the highly vascularized bone tissue in a process requiring angiogenesis and capillary ingrowth.
  • VEGF-B is not expressed by the cartilage but instead in the surrounding perichondrium.
  • the perichondrium provides a matrix for capillaries invading the ossifying bone and thereby has an essential role during bone formation.
  • the expression of VEGF-B in the perichondrium of developing bones of the vertebral column and the extremities as well as the epiphysis of the growing long bone supports an important role played by VEGF-B in the angiogenic processes which underlie capillary ingrowth into the developing bone tissue.
  • VEGF-B specific staining of VEGF-B was found in the choroid plexus beginning at E12.5, when this structure develops, and continuing throughout further development.
  • VEGF-B expression in other sites of the brain was confined to the smooth muscle cells of the arteries, such as the basilar artery. This expression started at E12.5, corresponding with the appearance of the smooth muscle cells of the carotid and subcalvian arteries. No expression was detected in the pericytes surrounding the capillary network of the brain.
  • E17.5 the brown fat expressed VEGF-B, most intensely in the vascular smooth muscle cells surrounding the larger vessels.
  • Figure 3G a strong immunoreactivity was seen at this time in the cortex of the fetal adrenal gland, identified by the arrow.
  • Expression of VEGF-B in the pancreatic primordium started around E12.5.
  • Figure 3H shows that at E17.5, the staining was confined to clusters of glandular cells which constitute the future exocrine pancreas.
  • VEGF-B mRNA and protein was consistently observed in the developing heart, various other striated muscles including many skeletal muscles and smooth muscle cells of the larger vessels. It is notable that high levels of VEGF-B mRNA have been observed in the corresponding tissues also in the adult animal (Olofsson et al . , Proc . Natl . Acad. Sci . USA, 199693: 2576-2581; Olofsson et al . , J. Biol . Chem. , 1996271: 19310-19317) . In addition, VEGF-B was expressed in the developing bone and cartilage, brown fat and in several organs including some exocrine and endocrine glands such as the pancreas and adrenal gland. No expression of VEGF-B was seen in the endothelial cells of the larger vessels or in capillaries of the different tissues.
  • VEGF-B vascular endothelial growth factor-B
  • VEGF-B vascular endothelial growth factor-B
  • VEGF-B might also regulate some other functions of the endothelium in these tissues in addition to serving as a potential growth regulatory molecule involved in the angiogenic processes during embryogenesis . Support for such a role comes from the observation that targeted inactivation of its receptor VEGFR-1, which resulted in failure to assemble endothelial lumens in the otherwise well developed vascular system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à l'expression du VEGF-B pour le développement osseux. Elle se rapporte à des méthodes visant à stimuler l'angiogenèse d'un os, à stimuler la cicatrisation de fractures ou cassures osseuses, à améliorer l'assimilation d'un implant et/ou sa fixation à un os et à traiter ou soulager les inflammations de l'épiphyse d'un os long. L'invention se rapporte également à l'utilisation d'une composition pharmaceutique qui contient un polypeptide ayant une séquence d'acides aminés dotée d'une similitude d'au moins 85 % avec la séquence SEQ ID NO: 2 ou 4, ou un fragment d'un tel peptide présentant l'activité biologique du VEGF-B permettant la stimulation de l'angiogenèse des os.
PCT/US2000/011096 1999-04-26 2000-04-26 Role du facteur-b (vegf-b) de croissance endotheliale dans le developpement osseux et utilisations correspondantes WO2000064261A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46624/00A AU4662400A (en) 1999-04-26 2000-04-26 Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13093599P 1999-04-26 1999-04-26
US60/130,935 1999-04-26

Publications (2)

Publication Number Publication Date
WO2000064261A1 true WO2000064261A1 (fr) 2000-11-02
WO2000064261A9 WO2000064261A9 (fr) 2002-04-04

Family

ID=22447069

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011096 WO2000064261A1 (fr) 1999-04-26 2000-04-26 Role du facteur-b (vegf-b) de croissance endotheliale dans le developpement osseux et utilisations correspondantes

Country Status (2)

Country Link
AU (1) AU4662400A (fr)
WO (1) WO2000064261A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022095A1 (fr) * 2002-09-04 2004-03-18 Abtech Anticorps anti-idiotypiques utiles en tant qu'agonistes d'un recepteur vegf ou fgf pour la therapie osseuse
EP1581241A2 (fr) * 2001-06-20 2005-10-05 Ludwig Institute For Cancer Research Stimulation de la vascularisation avec vegf-b
EP2476427A3 (fr) * 2004-08-02 2012-10-03 Zenyth Operations PTY. Ltd. Procédé de traitement de cancer comportant un antagoniste VEGF-B

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5840693A (en) * 1995-03-01 1998-11-24 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5840693A (en) * 1995-03-01 1998-11-24 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OLOFSSON ET. AL.: "Vascular endothelial growth factor B, a novel growth factor for endothelial cells", PROC. NATL. ACAD. SCI.USA, vol. 93, 1996, pages 2576 - 2581, XP002910092 *
RISTIMAKI ET. AL.: "Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial groowth factor-C", BIOL. CHEM., vol. 273, no. 14, 3 April 1998 (1998-04-03), pages 8413 - 8418, XP002928548 *
TOWNSON ET. AL.: "Characterization of the murine VEGF-related factor gene", BIOCHEM. BIOPHYS. RES. COMM., vol. 220, 1996, pages 922 - 928, XP002928549 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581241A2 (fr) * 2001-06-20 2005-10-05 Ludwig Institute For Cancer Research Stimulation de la vascularisation avec vegf-b
EP1581241A4 (fr) * 2001-06-20 2005-11-09 Ludwig Inst Cancer Res Stimulation de la vascularisation avec vegf-b
US7709450B2 (en) 2001-06-20 2010-05-04 Ludwig Institute For Cancer Research Stimulation of vascularization with VEGF-B-186
WO2004022095A1 (fr) * 2002-09-04 2004-03-18 Abtech Anticorps anti-idiotypiques utiles en tant qu'agonistes d'un recepteur vegf ou fgf pour la therapie osseuse
EP2476427A3 (fr) * 2004-08-02 2012-10-03 Zenyth Operations PTY. Ltd. Procédé de traitement de cancer comportant un antagoniste VEGF-B
US8822644B2 (en) 2004-08-02 2014-09-02 Zenyth Operations Pty Ltd Method of treating cancer comprising a VEGF-B antagonist

Also Published As

Publication number Publication date
AU4662400A (en) 2000-11-10
WO2000064261A9 (fr) 2002-04-04

Similar Documents

Publication Publication Date Title
EP1054687B1 (fr) Vecteurs d'expression et lignees cellulaires exprimant le facteur de croissance endothelial vasculaire d, et procede de traitement des melanomes
US6706687B1 (en) Platelet-derived growth factor D
US6541008B1 (en) Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof
US20030125537A1 (en) Vascular endothelial growth factor D(VEGF-D) antibodies and vectors, and methods of use
US7408040B2 (en) Antibodies to PDGF-D
US20070042413A1 (en) Platelet-derived growth factor D, DNA coding therefor, and uses thereof
JP2002525086A (ja) 血小板由来増殖因子ｃ、それをコードするｄｎａ、及びその利用法
US20020164687A1 (en) Platelet-derived growth factor C, DNA coding therefor, and uses thereof
JP2004527462A (ja) 血管新生活性のｉｎｖｉｖｏ刺激
WO2000064261A1 (fr) Role du facteur-b (vegf-b) de croissance endotheliale dans le developpement osseux et utilisations correspondantes
US20070172423A1 (en) Composition and method for modulating vasculogenesis for angiogenesis
AU2001280841A1 (en) Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
AU765888B2 (en) Expression vectors and cell lines expressing vascular endothelial growth factor D, and method of treating melanomas
US20030082670A1 (en) Platelet-derived growth factor C, DNA coding therefor, and uses thereof
US20050209136A1 (en) Method for stimulating connective tissue growth or wound healing
AU6502999A (en) Platelet-derived growth factor c, dna coding therefor, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN FI JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA CN FI JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: JP